#Germany #Cell Therapy #Minaris Advanced Therapies #GMP Facility #Taufkirchen

Minaris Advanced Therapies: A New Era in Global Therapeutics

In a significant move for the biotechnology industry, Minaris Advanced Therapies has officially opened its latest Good Manufacturing Practices (GMP) facility located in Taufkirchen, near Munich, Germany. This modern facility is designed to reinforce Minaris' position as a leading contract development and manufacturing organization (CDMO) in the ever-evolving arena of cell and gene therapy.

Strategic Significance of the New Facility

The Taufkirchen facility marks a vital expansion of Minaris' global production network, driven by a decade of expertise in the clinical and commercial manufacturing of innovative therapies. With an aim to streamline operations, the facility consolidates various processes, including process and analytical development, under one roof. Positioned conveniently close to Munich International Airport, it offers logistical advantages for clients across Europe and beyond.

The facility is equipped with:

• - Six state-of-the-art Class B/A cleanrooms designed for sterile production.
• - A Class C cleanroom dedicated for bioreactors and closed systems, with configurations that can transition to Class A/B as needed.
• - Customizable cleanroom layouts and 224 m² of additional space for future expansions.
• - Independently controlled HVAC systems for each cleanroom suite, enhancing operational efficiency by minimizing downtime.
• - Dedicated laboratories for process development and quality control, as well as cryopreservation and storage facilities to manage biological materials effectively.
• - Enhanced alerting and safety systems ensuring a high-standard operational environment.

Commitment to Innovating Therapies

Dr. Orla Cloak, the CEO of Minaris Advanced Therapies, expressed enthusiasm about the opening, stating, "This facility represents a pivotal milestone in our mission to accelerate the development and manufacturing of transformative cell and gene therapies globally." This new facility not only boosts Minaris' European footprint but also enhances their ability to respond to customer demands with speed, quality, and scalability.

Iain Baird, Chairman of Minaris Advanced Therapies, added, "Our shared vision for the future of cell and gene therapy manufacturing is to be scalable, flexible, and globally integrated. The seamless transition to this facility reflects our team’s dedication in Germany and our steadfast commitment to providing long-term benefits to both clients and patients worldwide."

The Path Ahead

The inauguration ceremony held on July 31, underscored Minaris' strategic mission to remain at the forefront of the rapidly advancing field of cell and gene therapy. This facility is set to play a crucial role in addressing the growing demand for specialized therapies, significantly impacting patient outcomes.

Minaris Advanced Therapies, headquartered in Philadelphia, Pennsylvania, manages over 650,000 square feet of infrastructure across the US, Europe, and Asia. With more than 7,500 GMP batches produced and released, it has established a solid global network that supports therapy developers from early development stages, through clinical trials, to commercial production.

The advancements reflect Minaris' commitment to pioneering therapeutic solutions, providing hope and innovative treatments to those in need. As the world of healthcare continues to evolve, facilities like the one in Taufkirchen exemplify the intersection of innovation and patient-centric care, paving the way for a healthier future.

About Minaris Advanced Therapies and Altaris

Minaris Advanced Therapies is a prominent entity in the field of contract development, manufacturing, and testing, specializing in cell and gene therapies. It operates under the umbrella of Altaris, an investment company dedicated to acquiring and building entities in the health sector since its establishment in 2003. Altaris' focus remains on generating value in healthcare while delivering commendable financial returns to its investors, managing $10 billion in equity.

For additional details, insights, and updates on Minaris Advanced Therapies, visit their official website or reach out via their media contact.